Deadline: 19-Oct-22
The European Commission (EC) is pleased to announce an open call for the EIC Pathfinder Challenge: Cardiogenomics.
The overall aim of this Challenge is to pave the way for novel therapies for major CVD conditions including hemorrhagic and ischemic stroke, aneurysm, cardiomyopathy and certain types of arrhythmias and other conditions, for which no effective treatments are currently available.
Cardiogenomics holds the potential to address existing gaps in the diagnosis and treatment of cardiovascular diseases (CVD), which would enable better outcome for the patient. Advanced genetic testing taking into account complex inheritance, or combining genetic testing, transcriptomics, proteomics and metabolomics analysis with clinical phenotype can improve clinical management of the CVD and identify more accurately, who is likely to be at risk for major cardiovascular events such as heart failure or sudden death.
Objectives
The following specific objectives have been identified for this Challenge:
- to identify single or multiple gene variants of high biological significance or other key molecules associated with the CVDs that would allow for accurate stratification of patients and guide the physician in their clinical management and monitoring of these CVDs;
- to identify novel targets based on these variants for specific CVD indication(s) that would allow for the development of first in class therapies for the same indication;
- to seek for novel technological solutions that could contribute to the development and acceleration of first in class therapies for major CVD conditions for which no effective treatments are currently available.
Funding Information
Up to Euro 167.00 Million available.
Expected Outcomes and Impacts
The following major impacts can be foreseen for this Challenge:
- impact on the practice of cardiology: identification of pathogenic mutations or multiple variants that have actionable effects (by disrupting normal biochemical pathways associated with the cause and/or progression of the disease), will have a substantive impact on the practice of cardiology;
- accelerating the implementation of personalised care in CVD: deciphering the molecular pathogenesis underlying the clinical pathology of a CVD disease, is key for implementing personalised care. Performing targeted DNA sequencing on CVD patient(s) to identify previously characterised pathogenic mutations, is expected to become part of the daily clinical routine in the CVD clinics. Targeted genetic testing is envisaged to serve a triple purpose:
- to achieve an early and more accurate diagnosis;
- to guide the physician to administer the right treatment for the right patient (personalised treatment); and
- to predict more accurately post treatment clinical course (favorable or non- clinical prognosis).
- gathering the necessary knowledge and data that would enable to apply disease modelling for CVD, including through 3D in-vitro models, to be used for screening drugs/therapies for CVDs.
Eligibility Criteria
- Any legal entity, regardless of its place of establishment, including legal entities from non-associated third countries or international organisation (including international European research organisations) is eligible to participate (whether it is eligible for funding or not), provided that the conditions laid down in the Rules for Participation have been met together with any other conditions laid down in the specific call or topic.
- In order to be eligible for funding, the applicants must be established in one of the eligible countries, i.e., Member States (including their outmost regions and overseas countries and territories (OCTs)), countries associated to Horizon Europe and low- and middle-income third countries.
- In order to be eligible for funding, the applicants must be established in one of the eligible countries, i.e.:
- Member States of the European Union (including overseas countries and
- territories (OCTs))
- Eligible non-EU countries:
- countries associated to Horizon Europe
- Low- and middle-income countries.
For more information, visit https://bit.ly/3OlQljJ
